ClinicalTrials.gg
CompletedNCT03962062Updated Sep 5, 2025Results posted

A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years

A Phase 1 interventional study of Moxidectin in Onchocerciasis, sponsored by Medicines Development for Global Health. Completed at 1 site in Ghana. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Medicines Development for Global Health · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
4 Years to 17 Years
Sex
All
01

Study summary

The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over. The secondary purpose is to evaluate the safety and pharmacokinetics of a single dose of moxidectin in children and adolescents aged 4 to 17 years.

02

Conditions studied

  • Onchocerciasis

Browse trials for

03

In context

Onchocerciasis

35 studies on the registry are indexed under Onchocerciasis; 7 are open to participants now.

This study's enrollment of 36 is below the median of 216 across 26 interventional studies indexed under Onchocerciasis.

Browse Onchocerciasis studies →

Lead sponsor

Medicines Development for Global Health is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 4 to 17 years, inclusive:

    1. Cohort I: 12 to 17 years;
    2. Cohort II: 8 to 11 years;
    3. Cohort III: 4 to 7 years;
  2. Live in a region designated by the World Health Organization (WHO) as endemic for O. volvulus infection (World Health Organization, 2019). Specifically, participants will be recruited from the Kpassa sub-district of the Nkwanta North district.The specific communities will include Wii, Jagri-Do, and Azua where mass drug administration with ivermectin for onchocerciasis commenced in October 2017;
  3. Willing and able to remain at the study clinic from Screening up to Day 7;
  4. Provision of parental or guardian written and assent / lack of expression of 'deliberate objection' (as appropriate for age);
  5. Females of must commit to using a reliable method of as per local family planning guidelines from Baseline (pre-treatment on Day 0) until approximately 6 months after treatment with study drug.

Exclusion criteria

Exclusion Criteria:

  1. History of serious medical or psychiatric condition which, in the opinion of the investigator, would put the subject at increased risk by participating in the study or jeopardize study outcomes;
  2. Known or suspected concurrent renal, cardiac, pulmonary, vascular, metabolic (thyroid disorders, adrenal disease), immunological disorders or , congenital heart disease, chronic lung disease;
  3. Has received an product within 28 days or 5 half-lives of Baseline, whichever is longer;
  4. Has received ivermectin or any other anti-helminthic treatments within 28 days of Baseline;
  5. Has received a vaccination within 7 days of Baseline;
  6. Known or suspected to macrocyclic lactones or used in the formulation of moxidectin;
  7. Poor venous access;
  8. Unable to swallow tablets (flat oval, 8.0 millimeters (mm) x 4.5 mm x 3.0 mm);
  9. Weight:

    1. Cohort I (12 to 17 years): \< 30 kg;
    2. Cohort II (8 to 11 years): \< 18 kg;
    3. Cohort III (4 to 7 years): \< 12 kg;
  10. Clinically relevant laboratory abnormalities at Screening, including:

    1. \< 9.5 grams per deciliter (g/dL);
    2. Neutrophil (granulocyte) count \< 1.5 x 109/L;
    3. count \< 110 x 109/L;
    4. (ALT) > 1.5 times the (ULN);
    5. Total > 1.5 times ULN;
  11. , , or (HIV) positive;
  12. Known or suspected malaria or other ongoing viral, bacterial, or plasmodium infection at Screening and/or Baseline;
  13. Loa loa co-infection;
  14. Unwilling, unlikely or unable to comply with all protocol specified assessments;
  15. For females of child bearing potential, pregnant or breastfeeding, or planning to become pregnant;
  16. Previous enrolment in this study;
  17. Is a sibling of another child already enrolled in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1: 12-17 years

    Moxidectin 8mg per oral, single dose

    Drug: Moxidectin

  • Experimental
    Cohort 2: 8-11 years

    Moxidectin 8mg (or lower dose) per oral, single dose

    Drug: Moxidectin

  • Experimental
    Cohort 3: 4-7 years

    Moxidectin single dose, determined by population pharmacokinetic modelling including data from Cohorts 1 and 2

    Drug: Moxidectin

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve of Moxidectin.

    Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.

    Time frame: Pre-dose (Screening) and post-dose at Hours 1, 2, 4, 8, 24 and 72 and Days 7, 14 and 28.

Secondary outcomes

  1. Area Under the Concentration Versus Time Curve (Zero to Infinity) of Moxidectin

    Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.

    Time frame: Pre-dose (Screening) and post-dose at Hours 1, 2, 4, 8, 24 and 72, Days 7, 14 and 28 and Week 12.

  2. Maximum Observed Plasma Concentrations (Cmax) of Moxidectin

    Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.

    Time frame: Pre-dose (Screening) and post-dose at Hours 1, 2, 4 and 8.

  3. Incidence and Severity of Adverse Events.

    Incidence and severity of adverse events, assessed by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Paediatric Adverse Events, Version 2.1.

    Time frame: Day 0 to Week 24 inclusive.

07

Results

Posted Jan 22, 2025

Participant flow

The first participant was screened on 29 March 2021 and the last participant last study visit was completed on 28 September 2022. Participants were recruited from communities in the Kpassa sub-district of the Oti region in Ghana, which is endemic for onchocerciasis.

Participant flow — Overall Study
Milestone12 to 17 Years MOX 8 mg8 to 11 Years MOX 8 mg8 to 11 Years MOX 6 mg4 to 7 Years MOX 4 mg
Started9999
Completed9999
Not completed0000

Outcome measures

PrimaryArea Under the Plasma Concentration Versus Time Curve of Moxidectin.

Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.

Time frame:
Pre-dose (Screening) and post-dose at Hours 1, 2, 4, 8, 24 and 72 and Days 7, 14 and 28.
Reported as:
Geometric mean · (hr*ng/mL)/mg
Area Under the Plasma Concentration Versus Time Curve of Moxidectin.
(hr*ng/mL)/mg12 to 17 Years MOX 8 mg8 to 11 Years MOX 6 mg8 to 11 Years MOX 8 mg4 to 7 Years MOX 4 mg
Area Under the Plasma Concentration Versus Time Curve of Moxidectin.2680 ± 24.72230 ± 52.33310 ± 23.01880 ± 26.5
SecondaryArea Under the Concentration Versus Time Curve (Zero to Infinity) of Moxidectin

Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.

Time frame:
Pre-dose (Screening) and post-dose at Hours 1, 2, 4, 8, 24 and 72, Days 7, 14 and 28 and Week 12.
Reported as:
Geometric mean · (hr*ng/mL)/mg
Area Under the Concentration Versus Time Curve (Zero to Infinity) of Moxidectin
(hr*ng/mL)/mg12 to 17 Years MOX 8 mg8 to 11 Years MOX 6 mg8 to 11 Years MOX 8 mg4 to 7 Years MOX 4 mg
Area Under the Concentration Versus Time Curve (Zero to Infinity) of Moxidectin3140 ± 24.82490 ± 59.23780 ± 29.22000 ± 29.3
SecondaryMaximum Observed Plasma Concentrations (Cmax) of Moxidectin

Moxidectin concentration in plasma collected at pre-specified intervals after dosing with oral moxidectin determined using a validated liquid chromatography-mass spectrometry(MS)/MS method.

Time frame:
Pre-dose (Screening) and post-dose at Hours 1, 2, 4 and 8.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentrations (Cmax) of Moxidectin
ng/mL12 to 17 Years MOX 8 mg8 to 11 Years MOX 6 mg8 to 11 Years MOX 8 mg4 to 7 Years MOX 4 mg
Maximum Observed Plasma Concentrations (Cmax) of Moxidectin83.1 ± 19.182.1 ± 41.2115 ± 25.686.4 ± 28.3
SecondaryIncidence and Severity of Adverse Events.

Incidence and severity of adverse events, assessed by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Paediatric Adverse Events, Version 2.1.

Time frame:
Day 0 to Week 24 inclusive.
Reported as:
Count of participants · Participants
Incidence and Severity of Adverse Events.
Participants12 to 17 Years MOX 8 mg8 to 11 Years MOX 6 mg8 to 11 Years MOX 8 mg4 to 7 Years MOX 4 mg
All Treatment-emergent Adverse Events (TEAEs)4767
TEAEs by Severity Grade 1 Mild3666
Grade 2 Moderate1112
Grade 3 Severe0001
Grade 4 Life-threatening0000

Adverse events

Collected over Day 0 to 24 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
12 to 17 Years MOX 8 mg0/9 (0%)0/9 (0%)4/9 (44.4%)
8 to 11 Years MOX 6 mg0/9 (0%)0/9 (0%)7/9 (77.8%)
8 to 11 Years MOX 8 mg0/9 (0%)0/9 (0%)6/9 (66.7%)
4 to 7 Years MOX 4 mg0/9 (0%)0/9 (0%)7/9 (77.8%)
Overall0/36 (0%)0/36 (0%)24/36 (66.7%)
Most frequent other events
Showing 10 of 13
Most frequent other events
Event12 to 17 Years MOX 8 mg8 to 11 Years MOX 6 mg8 to 11 Years MOX 8 mg4 to 7 Years MOX 4 mgOverall
MalariaInfections and infestations1/95/94/94/914/36
Abdominal painGastrointestinal disorders0/90/92/91/93/36
DiarrhoeaGastrointestinal disorders0/92/90/91/93/36
Upper respiratory tract infectionInfections and infestations1/91/91/90/93/36
ConjunctivitisInfections and infestations0/91/91/90/92/36
Abscess limbInfections and infestations0/90/90/91/91/36
Hookworm infectionInfections and infestations0/90/90/91/91/36
Tinea versicolourInfections and infestations1/90/90/90/91/36
VomitingGastrointestinal disorders0/90/90/91/91/36
AnaemiaBlood and lymphatic system disorders0/90/90/91/91/36

Baseline characteristics

Demographic and Baseline characteristics were analyzed in the Safety Analysis Set, which included all participants who provided signed informed consent/ assent and whose eligibility was confirmed on Day 0, and the Pharmacokinetic Analysis Set, which included all participants who received moxidectin and provided a minimum number of plasma samples for the determination of PK parameters. As no subjects were excluded from any analysis set, the data within these data sets is identical.

Age, Continuous
Age, Continuous(years)12 to 17 Years Moxidectin 8 mg8 to 11 Years Moxidectin 6 mg8 to 11 Years Moxidectin 8 mg4 to 7 Years Moxidectin 4 mgTotal
Mean13.7 ± 1.669.1 ± 1.059.7 ± 0.875.4 ± 1.339.5 ± 3.19
Sex: Female, Male
Sex: Female, Male(Participants)12 to 17 Years Moxidectin 8 mg8 to 11 Years Moxidectin 6 mg8 to 11 Years Moxidectin 8 mg4 to 7 Years Moxidectin 4 mgTotal
Female465621
Male534315
Race (NIH/OMB)
Race (NIH/OMB)(Participants)12 to 17 Years Moxidectin 8 mg8 to 11 Years Moxidectin 6 mg8 to 11 Years Moxidectin 8 mg4 to 7 Years Moxidectin 4 mgTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American999936
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)12 to 17 Years Moxidectin 8 mg8 to 11 Years Moxidectin 6 mg8 to 11 Years Moxidectin 8 mg4 to 7 Years Moxidectin 4 mgTotal
Ghana999936
Height
Height(cm)12 to 17 Years Moxidectin 8 mg8 to 11 Years Moxidectin 6 mg8 to 11 Years Moxidectin 8 mg4 to 7 Years Moxidectin 4 mgTotal
Mean149.74 ± 10.318130.09 ± 9.307133.11 ± 10.590108.81 ± 7.922130.44 ± 17.381
Weight
Weight(kg)12 to 17 Years Moxidectin 8 mg8 to 11 Years Moxidectin 6 mg8 to 11 Years Moxidectin 8 mg4 to 7 Years Moxidectin 4 mgTotal
Mean39.42 ± 8.75425.89 ± 4.56727.13 ± 4.84416.90 ± 2.66227.34 ± 9.766
BMI
BMI(kg/m2)12 to 17 Years Moxidectin 8 mg8 to 11 Years Moxidectin 6 mg8 to 11 Years Moxidectin 8 mg4 to 7 Years Moxidectin 4 mgTotal
Mean17.39 ± 1.74515.19 ± 1.06815.23 ± 1.12014.20 ± 0.91915.50 ± 1.683
Mean upper arm circumference at Screening
Mean upper arm circumference at Screening(cm)12 to 17 Years Moxidectin 8 mg8 to 11 Years Moxidectin 6 mg8 to 11 Years Moxidectin 8 mg4 to 7 Years Moxidectin 4 mgTotal
Mean21.78 ± 2.06518.42 ± 0.98118.66 ± 1.59115.68 ± 1.34718.63 ± 2.644
08

Study locations

1 site
  • University of Health and Allied Services School of Public Health
    Hohoe, Volta Region, Ghana
09

References and documents

Publications

  • Opoku NO, Doe F, Agbogah ME, Laryea R, Gordor SK, Donkor BS, Anyomitse E, Kugali D, van Zutphen-van Geffen M, Navarro DJ, Rayner CR, Patel K, Kuesel AC, Lowe M, Kinrade S. Identification of a moxidectin dose for 4- to 11-year-old children to support registration and potential use for onchocerciasis elimination: results of an open-label pharmacokinetic and safety study. Parasit Vectors. 2025 Jul 24;18(1):295. doi: 10.1186/s13071-025-06891-z. PubMed 40707999 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Deidentified individual participant data in the form of data listings and SDTM and ADaM datasets may be available for sharing on application to the Sponsor.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will become available 12 months after publication.

Access criteria: Provision of a methodologically sound and relevant proposal detailing the intended use of the data and relevant ethics approval for the proposed analysis, as applicable.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in May 2022, 14 months.

Results were first posted in Jan 2025, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2019
First posted
May 23, 2019
StartActual
Mar 29, 2021
Primary completionActual
May 30, 2022
CompletionActual
Sep 28, 2022
Results first posted
Jan 22, 2025
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03962062
Lead sponsor
Medicines Development for Global Health
Responsible party
Sponsor
First posted
May 23, 2019
Start date
Mar 29, 2021
Primary completion
May 30, 2022
Completion
Sep 28, 2022
Results posted
Jan 22, 2025
Last update
Sep 5, 2025

Study contacts

Nicholas O Opoku, MD
principal investigator · University of Health and Allied Sciences School of Public Health, Hohoe, Ghana

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxidectin

Start the discussion